Dimensional Fund Advisors LP increased its stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 4.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,067,951 shares of the biopharmaceutical company's stock after buying an additional 171,933 shares during the period. Dimensional Fund Advisors LP owned 3.09% of Dynavax Technologies worth $51,948,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DVAX. Russell Investments Group Ltd. increased its position in shares of Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares during the period. Smartleaf Asset Management LLC increased its holdings in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 2,034 shares during the period. GAMMA Investing LLC increased its holdings in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after purchasing an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Dynavax Technologies in the 4th quarter worth $71,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 1,076 shares in the last quarter. Institutional investors own 96.96% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on DVAX shares. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. The Goldman Sachs Group reduced their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research note on Thursday, April 17th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st.
Read Our Latest Stock Analysis on DVAX
Dynavax Technologies Stock Performance
DVAX stock opened at $11.33 on Friday. The firm has a 50-day simple moving average of $12.59 and a two-hundred day simple moving average of $12.58. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.63. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of 62.94 and a beta of 1.26.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, equities analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.
Dynavax Technologies Company Profile
(
Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Read More
Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
